Gaudium IVF IPO GMP Today: 11% Listing Gain Or Cooling Hype? Full Breakdown For Investors
Gaudium IVF IPO GMP Today: 11% Listing Gain Or Cooling Hype? Full Breakdown For Investors
The keyword gaudium ivf ipo gmp is trending hard right now. Retail investors are checking subscription numbers every few hours. GMP updates are being refreshed again and again. And honestly, this IPO has grabbed attention because it is India’s first listed fertility care focused company.
Gaudium IVF and Women Health Ltd opened its ₹165 crore IPO on February 20, 2026. On Day 1 itself, retail participation looked strong. But at the same time, GMP has cooled from earlier highs. So the big question is simple. Is this a steady long term play or just a moderate listing gain story?
Before you apply, let us break everything in simple language.
Key Takeaways
- IPO size is ₹165 crore with price band ₹75 to ₹79 per share
- Lot size is 189 shares. Minimum investment around ₹14,931
- Day 1 subscription around 40 to 50 percent. Retail leading
- GMP currently ₹8.5. Earlier it was ₹12 to ₹15
- Estimated listing price around ₹87.5
- Industry growing at 13 percent CAGR till 2034
- Company expanding from 7 hubs to 26 hubs in coming years
- Risks include doctor dependency, high attrition, tax dispute and valuation concerns
- Most brokerages giving Subscribe for long term view
IPO Structure And Important Dates
The IPO is a book built issue. It includes fresh issue of ₹90 crore and offer for sale of ₹75 crore. Listing will happen on:
- BSE
- National Stock Exchange of India
Tentative listing date is February 27, 2026. Allotment expected on February 25.
Quick IPO Snapshot
| Particular | Details |
|---|---|
| Issue Size | ₹165 crore |
| Price Band | ₹75 to ₹79 |
| Lot Size | 189 shares |
| Min Investment | ₹14,931 |
| Fresh Issue | ₹90 crore |
| OFS | ₹75 crore |
| Pre IPO Market Cap | ~₹575 crore |
Anchor investors already invested ₹49.5 crore before opening. That gave early confidence signal.
Gaudium IVF IPO GMP Today And What It Means
Right now, GMP is ₹8.5.
At upper band ₹79, expected listing price comes near ₹87.5. That means around 10.7 percent potential listing gain. But here is the catch.
Earlier GMP was ₹12 to ₹15. That was indicating 15 to 19 percent premium. Now it has cooled. That tells you sentiment is positive but not crazy bullish.
Grey Market Premium is unofficial. It is driven by demand and mood of market. It can change quickly. So do not take it as guarantee. Current mood is moderate optimism. Not blockbuster. Not negative.
Also Read: Accenture AI Strategy 2026: Promotions Linked To AI Usage And The Big Agentic Bet
Subscription Status Day 1 Analysis
As per midday updates:
- Overall subscription around 40 to 50 percent
- Retail portion around 0.7 to 0.8 times
- NII around 0.3 to 0.4 times
- QIB participation minimal initially
Retail investors seem more excited. Institutions are waiting.
This pattern usually means listing gains could be decent but not explosive unless QIB money comes strongly in last two days.
Industry Growth Story Looks Solid
This is where things get interesting.
Indian IVF industry is projected to grow from 1.32 billion USD in 2024 to 4.54 billion USD by 2034. That is around 13 percent CAGR.
Key drivers:
- Rising infertility due to lifestyle factors
- Delayed parenthood
- Rising maternal age
- Increasing awareness about ART procedures
- Cost advantage compared to US and Europe
- Medical tourism demand
India IVF cycle cost is around 3000 to 4000 USD. In US it can go up to 15000 to 20000 USD. That gap is huge.
Also around 70 percent of market is still unorganised. Management claims 98 percent opportunity still untapped. That gives long runway for growth.
Business Model And Expansion Plan
The company follows hub and spoke model.
Currently:
- 7 hubs
- 28 spokes
- 30 plus locations including Delhi, Mumbai, Bengaluru, Patna, Srinagar and others
Revenue comes mainly from:
- IVF cycles
- ICSI
- IUI
- Fertility preservation
- Diagnostic services
- Gynaecological procedures
Expansion plan is aggressive.
They want to scale hub network from 7 to 26 in next few years. That is almost 3.7 times growth in capacity. If new centers mature well, operating leverage can improve margins.
Financial Performance Snapshot
Let us look at numbers.
| Financial Year | Revenue | PAT |
|---|---|---|
| FY24 | ₹47.89 crore | ₹10.31 crore |
| FY25 | ₹70.72 crore | ₹19.13 crore |
Revenue growth is strong. Profit almost doubled year on year.
EBITDA margins around 40 percent as per some brokerage estimates. That is healthy for healthcare service platform.
Half year FY26 numbers also show continued momentum. So financially company is growing. That part looks clean.
What Public Is Saying On X
Sentiment on X is mostly balanced.
People are discussing:
- Retail subscription updates
- GMP changes
- Sector potential
- Risks like doctor attrition
There is no crazy hype. No panic negativity either.
Retail investors are excited about being first fertility focused listed company in India.
Long term investors are liking demographic story.
Some are cautious because GMP is cooling. Many posts say apply after reading RHP and fundamentals. That is actually a healthy sign.
Key Strengths Investors Are Liking
- First mover advantage in listed fertility space
- Scalable hub and spoke model
- Strong FY25 profit growth
- Asset light expansion
- Medical tourism opportunity
- Industry tailwinds
Brokerages like SMIFS, BP Wealth and others have given Subscribe rating mainly for long term.
Risks You Should Not Ignore
Every IPO has risks. This one also has.
- High dependency on doctors and embryologists
- Attrition rate above 30 percent
- Contingent liabilities around ₹45 crore
- Tax dispute around ₹31 crore
- Valuation around 23 to 30 times FY25 earnings
- Past negative cash flows
Healthcare businesses depend heavily on skilled professionals. If key doctors leave, performance can get affected.
Valuation is not dirt cheap. It is fairly priced. So listing pop may not be massive.
Should You Apply For Gaudium IVF IPO?
If you are looking only for quick listing gains, current GMP suggests around 10 percent potential upside. That is decent but not mind blowing.
If you are looking at 2 to 3 year horizon, industry growth story looks attractive. Fertility services demand is structural. Urban lifestyle changes are real.
But keep risk in mind. Doctor retention and expansion execution are critical.
This IPO suits:
- Investors with moderate risk appetite
- People who believe in healthcare growth story
- Investors who can hold for medium term
It may not suit those expecting 30 to 40 percent listing jump.
Final Verdict On Gaudium IVF IPO GMP
Right now story is simple.
GMP is positive but cooling. Retail interest is strong. Industry outlook is strong. Financial growth is visible. Valuation is fair. So this is not a hype IPO. It is more of a steady healthcare growth play.
If broader market stays stable, listing around ₹85 to ₹90 range looks possible based on current sentiment. But final outcome depends on last two days subscription and overall market mood. Do your own research before applying. IPO investing always carries risk.
Related Posts :
Share This Post